This study was run to evaluate whether provider specialty is a driver for biosimilar adoption, defined as adoption probability difference (APD). Diane Faraone, PharmD, Russell Robbins, MD, MBA, Grace Kane, MS, Douglas Londono, PhD.  The US biologics market has significantly expanded in recent years; projected to reach $62 billion in prescription drug spend by 2025. Biosimilar…

PurpleLab® goes further than raw claims data, by serving longitudinal patient data in combination with our no-code HealthNexus platform, to deliver on-demand insights, in minutes. HealthNexus, harmonizes the complex intersections created by the array of disparate healthcare vocabularies that annotate the factual account of a patient’s journey along with the reporting dimensions of critical need….

The Data-Driven Path to Biosimilar Success | Data Dive with PurpleLab This podcast was created in collaboration with the Pharmacy Podcast Network. In this episode, we are exploring a fascinating topic: how real-world data is reshaping the landscape of biosimilars. Dr. Russell Robbins, Chief Medical Information Officer and Dr. Diane Faraone, Senior Director in Pharmacy…

Data-Driven Diversity: PurpleLab’s Approach to Inclusive Clinical Trials This podcast was created in collaboration with the Pharmacy Podcast Network. In this episode, we delve into the critical topic of Diversity, Equity, and Inclusion (DEI) in clinical trials. Todd introduces PurpleLab and welcomes Dr. Russell Robbins, Chief Medical Information Management for Life Sciences. Together, they explore…

Glucagon-like peptide-1 (GLP-1) agonists are a class of medications frequently used to treat type 2 diabetes mellitus (T2DM) and obesity.[1] This class of medications assists in lowering blood sugar levels and promotes weight loss. In addition to treating diabetics, these medications are also used to treat obesity in diabetics as well as non-diabetics.   GLP-1 drugs…

Open claims and closed claims data serve as vital tools for comprehending patients’ progress and engagements throughout their healthcare voyage. However, which data type proves most advantageous and under what circumstances? Whether the need is to assess the cost-effectiveness of a recently introduced medication or streamline clinical trial recruitment, both open claims data and closed…

As treatment options for patients are constantly evolving, staying ahead of the curve is critical for life science companies and physicians. But with so many options in the market, how can companies gain a competitive advantage with prescribers? By leveraging real-time data that offers unprecedented insights into physician behavior and patient outcomes. PurpleLab®, a healthcare…

Healthcare today is evolving into precision medicine, or what the FDA refers to as personalized medicine.  To stay competitive in the constantly shifting healthcare landscape, organizations across the healthcare ecosystem must embrace this targeted approach and leverage the tools needed to make safe decisions for their patients or populations. By unlocking insights provided from advanced…

The Skinny on Weight loss Drugs This podcast was created in collaboration with the Pharmacy Podcast Network. PurpleLab’s dataset from October 2022 – October 2023 shows that 2.8M people had been prescribed and dispensed a semaglutide drug.  PurpelLab’s database shows who really is getting access to the drugs by looking into:  States with most prescriptions (and zoom…